期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 6, 期 4, 页码 567-572出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.40
关键词
alpha 4 beta 7; adhesion; angiogenesis; CAM; Crohn's disease; inflammatory bowel disease; integrin; MAdCAM; molecules; natalizumab; ulcerative colitis; vedolizumab
类别
Inflammatory bowel bowel diseases share common pathogenetic mechanisms that are not yet completely understood. It is clear, however, that the expression and production of cytokines in response to inflammation plays a key role in mediating the migration of activated leukocytes. The process of angiogenesis and the expression of adhesion molecules on the intestinal microvasculature act as gateways, facilitating the recruitment of leukocytes into the gut mucosa. New agents specifically blocking adhesion molecules, in particular integrins, have been developed in order to limit the passage of activated leukocytes into the mucosa. Non-gut-specific anti-ntegrin agents, such as natalizumab, have been shown to be effective in the treatment of IBD, but the risk of serious adverse events has limited their further development. The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial. This novel specific anti-integrin drug seems to hold promise in the treatment of gut inflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据